Trial Profile
A Single-Arm, Open-Label Study of the Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Red Blood Cell Transfusion-Dependent Myelodysplastic Syndromes.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Ciclosporin
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 01 Nov 2019 Status changed from completed to discontinued.
- 08 Mar 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 08 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.